Pfizer’s Prevnar posts .53B in Q4 sales, handily beating consensus Pfizer’s Prevnar turned in consensus-beating sales of $1.53 billion—up 7% over the same period last year—thanks to government purchases internationally […]
Repairing mutation ‘clusters’ with CRISPR could lead to broader Duchenne therapy Targeting “clusters” of mutations in the dystrophin gene could lead to a treatment for as many as 60% of […]
Pfizer pats itself on the back for tax reform lobbying, do-gooder investments On Pfizer’s fourth-quarter conference call, Morgan Stanley analyst David Risinger congratulated company executives on their “efforts to educate […]
Sage expands into sleep disorders after early-phase success Sage Therapeutics has added sleep disorders to the list of indications targeted by SAGE-217. The CNS specialist committed to initiating sleep disorder […]
What will Pfizer do with tax reform? It won’t revive a split, CFO says Pfizer’s finally getting what it always wanted in U.S. tax reform. And now, all eyes are […]
Roche’s pricey new hemophilia drug Hemlibra gets a rare blessing from U.S. cost watchdogs As the hemophilia market gets increasingly crowded, Roche needs all the help it can get generating […]
Pfizer confirms neuro cuts as it swings the ax on a host of other early projects Pfizer already forewarned that it was cutting jobs and projects out of its neuro […]
EMA to lose 50% of its floor space in move to temporary Amsterdam home The European Medicines Agency (EMA) will move into temporary accommodations half the size of its current […]
Sanofi expands U.S. biologics plant even as it strikes deals to stuff its pipeline Sanofi, which has been converting its biologics plant in Framingham, Massachusetts, to digital manufacturing, will again […]
SEC sues over suspected insider trading around Sanofi’s Bioverativ buy Did insider trading occur around Sanofi’s $11.6 billion deal for Bioverativ? The Securities and Exchange Commission thinks it may have—and […]